Department of Internal Medicine, Fatih University Medical School, Ankara, Turkey.
Med Princ Pract. 2011;20(4):332-5. doi: 10.1159/000324547. Epub 2011 May 11.
To evaluate the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) activity and also its relationship with other homeostasis markers in breast cancer patients.
Forty-two female patients with breast cancer and 24 healthy women (controls) were enrolled in the study and fasting blood samples of all cases were drawn from a large antecubital vein for assay of TAFI and other homeostasis tests.
The TAFI levels were 79.5 ± 15.5 and 39.3 ± 12.1 in patients and controls, respectively, and the difference was statistically significant (p < 0.001). In the patient group, the serum fibrinogen level was 504.9 ± 224.8, while in the control group it was 393.9 ± 100.5, and the difference was also statistically significant (p < 0.001).
The data showed that increased levels of TAFI are a contributing factor of thrombotic disorders in breast cancer patients.
评估乳腺癌患者凝血酶激活的纤溶抑制物（TAFI）活性水平及其与其他内稳态标志物的关系。
本研究纳入了 42 名女性乳腺癌患者和 24 名健康女性（对照组）。所有患者均从肘前大静脉抽取空腹血样，用于检测 TAFI 和其他内稳态指标。
患者组的 TAFI 水平为 79.5±15.5，对照组为 39.3±12.1，两组间差异具有统计学意义（p<0.001）。患者组的血清纤维蛋白原水平为 504.9±224.8，对照组为 393.9±100.5，两组间差异也具有统计学意义（p<0.001）。
研究数据表明，TAFI 水平升高是乳腺癌患者血栓形成紊乱的一个促成因素。
